Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Addict Med ; 2024 Apr 08.
Article in English | MEDLINE | ID: mdl-38587298

ABSTRACT

OBJECTIVES: Nonmedical use (NMU) of stimulants is an increasingly common phenomenon worldwide. Motivated by enhancing academic performance, peer pressure, and seeking pleasure, students in the Middle East are thought to be a high-risk population. This is especially important in times when the political instability in the region facilitates the production and trafficking of such substances. This study aimed to unveil the burden of NMU of stimulants and examine associated correlates among senior high school and university students in Jordan. METHODS: We describe a cross-sectional study of senior high school and university students in Jordan assessing NMU of stimulants. Data were collected between January and April of 2022 through a survey, which was distributed online leading to a google forms page. The survey queried sociodemographic characteristics, history of NMU of stimulants, use of other illicit substances, attitudes toward NMU of stimulants, as well as a mental health assessment. RESULTS: A total of 8739 students completed the survey (mean age of 20.40 ± 2.45 years), of which 5.1% reported a lifetime NMU of stimulants. Fenethylline (Captagon) was the most widely reported stimulant (2.6%). Living in the southern region, being diagnosed with a personality disorder, and using concomitant illicit substances were associated with the NMU of stimulants. CONCLUSIONS: The NMU of CNS stimulants, especially fenethylline, is prevalent in Jordan. More surveillance ought to be heeded toward the southern borders of Jordan. Students who use stimulants for academic reasons must be made aware of the potential consequences of the NMU of stimulants.

2.
Turk J Pediatr ; 62(6): 962-969, 2020.
Article in English | MEDLINE | ID: mdl-33372434

ABSTRACT

BACKGROUND: Our study aimed to compare the outcome of different therapeutic modalities for the management of children with Guillain-Barré syndrome (GBS) and to identify the associating risk factors that may affect the course and prognosis of the disease. METHODS: Our retrospective study compared the outcomes of different therapeutic regimens for patients with GBS who were admitted to Assiut University Children Hospital, Assiut, Egypt, from 2014 to 2016. RESULTS: The study included 50 patients diagnosed with GBS. Upper respiratory tract infection was the most prevalent preceding factor (66%). Acute inflammatory demyelinating polyneuropathy (AIDP) was the most prevalent type (80%). Regarding therapeutic modalities, 45 patients started with IVIG treatment, and five patients started plasmapheresis. Seventeen patients showed no improvement after two weeks of IVIG and received plasmapheresis as a sequential therapy. We found no patients who received plasmapheresis, followed by IVIG. Patients treated with plasmapheresis alone showed a significantly shorter duration of hospitalization and better outcomes in comparison to those treated with IVIG alone or with both modalities. CONCLUSIONS: AIDP was the most common variety of GBS in our study. GBS patients who were treated with plasmapheresis had a better outcome with a short duration of hospitalization.


Subject(s)
Guillain-Barre Syndrome , Universities , Child , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/epidemiology , Guillain-Barre Syndrome/therapy , Hospitals , Humans , Immunoglobulins, Intravenous/therapeutic use , Retrospective Studies
3.
Ann Saudi Med ; 23(5): 270-7, 2003.
Article in English | MEDLINE | ID: mdl-16868393

ABSTRACT

BACKGROUND: Secondary carnitine deficiency may develop in chronic renal failure (CRF) patients undergoing long-term hemodialysis (HD), with a resulting higher incidence of cardiovascular diseases, dyslipidemia and oxidative stress. We studied the efficacy of 12 months of L-carnitine supplementation on the amelioration of dyslipidemia, oxidative stress and cardiac dysfunction in 24 CRF children undergoing long-term HD compared with 24 age- and sex-matched controls. METHODS: Plasma samples were analyzed spectrophotometerically before and after dialysis sessions and after 2-month supplementation with oral L-carnitine (50 mg/kg/day) for free carnitine (FC), the lipid profile, and oxidative stress markers. Echocardiography the day following dialysis measured cardiac diameters, wall thicknesses, left ventricular mass index (MI), end diastole and systole volume indices and functions. RESULTS: The pre-dialysis FC concentration was substantially lower than controls and decreased significantly at the end of the dialysis session. Pre- and post-dialysis plasma levels of free fatty acids (FFAs), trigyleride (TG), total cholesterol (TC) and oxidative stress markers significantly increased while high-density lipoprotein cholesterol (HDL-C) and phospholipids significantly decreased compared to controls. Echocardiography detected a significant increase in cardiac diameters and thickness, and systolic and diastolic cardiac dysfunction. After L-carnitine supplementation, plasma levels of FC increased to normal levels. FFAs, TC and HDL-C returned to control levels while TG, phospholipids, and the oxidative stress markers decreased but remained significantly higher than controls. There was a significant decrease in cardiac diameters and an increase in left ventricular diastolic function (E/A ratio), but no correlation between FC levels and echocardiographic parameters. Pre-dialysis, post-dialysis and after treatment, plasma FC level showed a significant positive correlation with HDL-C and phospholipids and a significant negative correlation with each of oxidative stress markers, FFAs, TG and TC. On the other hand, FFAs showed a significant positive correlation with TG, TC, DC, NO and a significant negative correlation with HDL-C and phospholipids. CONCLUSION: This study demonstrates that CRF children under regular HD suffer from a decrease in the level of plasma FC, dyslipidemia, oxidative stress, and an increase in cardiac diameters and thickness with impairment of cardiac functions. Oral L-carnitine supplementation at a dose of 50 mg/kg for 2 months can increase plasma FC level, improve dyslipidemia, decrease oxidative stress with reduction of cardiac diameters and increase in diastolic function.

SELECTION OF CITATIONS
SEARCH DETAIL
...